Search Results - "Khraishi, Majed"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Biosimilars: A Multidisciplinary Perspective by Khraishi, Majed, MB, BCh, FRCPC, Stead, David, GPhC, MRPharmS, DMS, Lukas, Milan, MD, PhD, Scotte, Florian, MD, PhD, Schmid, Holger, MD, MSc

    Published in Clinical therapeutics (01-05-2016)
    “…Abstract A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient…”
    Get full text
    Journal Article
  6. 6

    Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians by Khraishi, Majed M.

    “…Abatacept is recommended by several expert consensus groups including the 2013 update of the EULAR recommendations for the pharmacologic management of…”
    Get full text
    Book Review Journal Article
  7. 7

    Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry by Rahman, Proton, Arendse, Regan, Khraishi, Majed, Sholter, Dalton, Sheriff, Maqbool, Rampakakis, Emmanouil, Lehman, Allen J, Nantel, Francois

    Published in BMJ open (13-08-2020)
    “…ObjectivesThe objectives of this study were to describe the demographic profile and baseline disease characteristics of patients with psoriatic arthritis (PsA)…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis by Khraishi, Majed, Millson, Brad, Woolcott, John, Jones, Heather, Marshall, Lisa, Ruperto, Nicolino

    Published in Pediatric rheumatology online journal (10-09-2019)
    “…In adult patients with arthritis, use of the tumor necrosis factor (TNF) inhibitor etanercept (ETN) is often associated with a reduction in the utilization of…”
    Get full text
    Journal Article
  12. 12
  13. 13

    Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study by Haraoui, Boulos, Jamal, Shahin, Ahluwalia, Vandana, Fung, Diana, Manchanda, Tarang, Khraishi, Majed

    Published in Rheumatology and therapy. (01-12-2018)
    “…Introduction This study was conducted to observe patterns of use of the interleukin-6 receptor-alpha inhibitor tocilizumab in routine clinical practice in…”
    Get full text
    Journal Article
  14. 14

    Safety profile of abatacept in rheumatoid arthritis: A review by Khraishi, Majed, MB, BCh, Russell, Anthony, MD, Olszynski, Wojciech P., MD, PhD

    Published in Clinical therapeutics (01-10-2010)
    “…Abstract Background: Abatacept, a soluble human fusion protein that selectively modulates the costimulatory signal required for full T-cell activation, is…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18

    Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network by Inman, Robert D, Choquette, Denis, Khraishi, Majed, Gladman, Dafna D, Hussein, Shamiza, Neish, Drew, Leclerc, Patrick

    Published in Journal of rheumatology (01-05-2023)
    “…Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition consisting of 2 clinical subsets: nonradiographic axSpA and ankylosing…”
    Get full text
    Journal Article
  19. 19

    Real-World Retention and Clinical Effectiveness of Secukinumab for Psoriatic Arthritis: Results From the Canadian Spondyloarthritis Research Network by Gladman, Dafna D, Choquette, Denis, Khraishi, Majed, Inman, Robert D, Hussein, Shamiza, Neish, Drew, Leclerc, Patrick

    Published in Journal of rheumatology (01-05-2023)
    “…Psoriatic arthritis (PsA) is an immune-mediated disease characterized by pain, stiffness, and swelling of peripheral joints, with an estimated prevalence in…”
    Get full text
    Journal Article
  20. 20

    Comparative overview of safety of the biologics in rheumatoid arthritis by Khraishi, Majed

    Published in Journal of rheumatology. Supplement (01-06-2009)
    “…Six biologic agents are currently available in Canada for the treatment of rheumatoid arthritis (RA): abatacept, adalimumab, anakinra, etanercept, infliximab,…”
    Get more information
    Journal Article